J. Clin. Med. 2015, 4(4), 696-714; https://doi.org/10.3390/jcm4040696
Concise Review: Methods and Cell Types Used to Generate Down Syndrome Induced Pluripotent Stem Cells
1
Department of Genetic Medicine and Development, University of Geneva Medical School and Geneva University Hospitals, 1 Rue Michel-Servet, CH-1211 Geneva, Switzerland
2
Department of Obstetrics and Gynecology, Cantonal Hospital of Fribourg, Chemin des Pensionnats 2-6, 1708 Fribourg, Switzerland
*
Authors to whom correspondence should be addressed.
Academic Editor: Michael J. Edel
Received: 9 February 2015 / Revised: 23 March 2015 / Accepted: 31 March 2015 / Published: 15 April 2015
(This article belongs to the Special Issue iPS Cells for Modelling and Treatment of Human Diseases)
Abstract
Down syndrome (DS, trisomy 21), is the most common viable chromosomal disorder, with an incidence of 1 in 800 live births. Its phenotypic characteristics include intellectual impairment and several other developmental abnormalities, for the majority of which the pathogenetic mechanisms remain unknown. Several models have been used to investigate the mechanisms by which the extra copy of chromosome 21 leads to the DS phenotype. In the last five years, several laboratories have been successful in reprogramming patient cells carrying the trisomy 21 anomaly into induced pluripotent stem cells, i.e., T21-iPSCs. In this review, we summarize the different T21-iPSCs that have been generated with a particular interest in the technical procedures and the somatic cell types used for the reprogramming. View Full-TextKeywords:
induced pluripotent stem cells; Down syndrome; trisomy 21; T21-iPSCs; reprogramming; isogenic iPSCs
▼
Figures
Figure 1
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).
Share & Cite This Article
MDPI and ACS Style
Hibaoui, Y.; Feki, A. Concise Review: Methods and Cell Types Used to Generate Down Syndrome Induced Pluripotent Stem Cells. J. Clin. Med. 2015, 4, 696-714.
Related Articles
Article Metrics
Comments
[Return to top]
J. Clin. Med.
EISSN 2077-0383
Published by MDPI AG, Basel, Switzerland
RSS
E-Mail Table of Contents Alert